Summary
Two formulations of L-648,051 (L) were studied [intravenous (i.v.) and aerosol (A)] in two separate trials. Study I (i.v.) involved 4 normal male subjects in a single blind dose ranging study where good systemic tolerability and safety was shown. However, dose dependent local irritation at the injection site was observed at all dose levels (35, 52.5 and 70 mg/5 min infusion). L has a high systemic clearance rate (1.2 l/min), a small volume of distribution (4.4 l) and a short plasma half-life (2.4 min).
Study II (A) involved 16 normal male volunteers who received incremental aerosolized doses of L from 0.1 to 1.6 mg in a double-blind, placebo controlled, dose ranging study. Complaints of mild local irritation or discomfort in the upper respiratory tract were the only significant findings. No dose relationship of these complaints could be shown.
In conclusion, L is a safe and well tolerated drug when administered by aerosol. It causes dose related local, but not systemic, adverse experiences when administered i.v. In view of this tolerability and of its demonstrated activity against LTD4-challenge in animals, clinical efficacy studies with the aerosol formulation are warranted.
Similar content being viewed by others
References
Grant JA, Lett-Brown MA (1986) Bronchial asthma leukocyte synthesis of slow-reacting substance of anaphylaxis, and other evidence for activation of blood cells in asthma. J Allergy Clin Immunol 77: 407–410
Dahlen SE (1983) Pulmonary effects of leukotrienes. Acta Physiol [Suppl 2]: 512
Lundgren JD, Shelhamer JH, Kaliner MA (1985) The role of eicosanoids in respiratory mucus hypersecretion. Ann Allergy 55: 5–11
Wasserman SI (1983) Mediators of immediate hypersensitivity. J Allergy Clin Immunol 72: 101–119
Leitch AG (1984) Leukotrienes and the lung. Clin Sci 67: 153–160
Barnes NC, Piper PJ, Costello JF (1984) Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 39: 500–504
Jones TR, Guindon Y, Young R, Champion E, Charette L, Denis D, Ethier D, Hamel R, Ford-Hutchinson AW, Fortin R, Letts G, Masson P, McFarlane C, Piechuta H, Rokach J, Yoakim C, DeHaven RN, Maycock A, Pong SS (1986) L-648,051, sodium 4-[3-(4-acetyl-3- hydroxy-2- propyl-phenoxy)-propyl sulfonyl]γ-oxo-benzenebutonoate: A leukotriene D4-receptor antagonist. Can J Physiol Pharmacol 64: 1535–1542
Rothwell CM, Hsieh JY-K, Bayne WF (1986) High-performance liquid chromatographic determination of 4-[3-(4-acetyl-3-hydroxy-2-propyl-phenoxy) propylsulphonyl]-γ-oxo-benzenebutanonic acid and metabolites in human plasma. J Chromatography V 417, N2, P447-SI, 1987
Author information
Authors and Affiliations
Additional information
Some of the data referred to in this paper have not been published but are held on file at the MSD Research Laboratories
Rights and permissions
About this article
Cite this article
Biollaz, J., Stahl, E., Hsieh, J.Y. et al. Tolerability and pharmacokinetics of L-648,051. A leukotriene D4-receptor antagonist, in healthy volunteers. Eur J Clin Pharmacol 33, 603–607 (1988). https://doi.org/10.1007/BF00542495
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542495